Sotera Health (NASDAQ:SHC) Given New $16.00 Price Target at Barclays

Sotera Health (NASDAQ:SHC) had its price objective lowered by equities researchers at Barclays from $17.00 to $16.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 28.31% from the company’s previous close.

SHC has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Citigroup boosted their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.92.

Sotera Health Stock Performance

NASDAQ:SHC traded up $0.19 during midday trading on Friday, reaching $12.47. 1,816,518 shares of the company traded hands, compared to its average volume of 979,003. The firm has a market capitalization of $3.53 billion, a price-to-earnings ratio of 49.88 and a beta of 1.91. The company has a fifty day moving average price of $13.46 and a 200 day moving average price of $14.52. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.08.

Institutional Investors Weigh In On Sotera Health

Institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its position in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after purchasing an additional 1,140 shares during the period. True Wealth Design LLC bought a new position in Sotera Health during the third quarter valued at about $32,000. Quarry LP acquired a new position in Sotera Health during the fourth quarter worth about $28,000. GAMMA Investing LLC raised its position in Sotera Health by 37.5% in the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after acquiring an additional 1,121 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in Sotera Health in the 3rd quarter valued at about $91,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.